John Smith
Family Medicine · Oneonta, ALNPI 1760553978
Payments from drug & device makers
Across 60 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$105
- Baxter Healthcare$105
- Boehringer Ingelheim$101
- Shire North American Group Inc$98
- Boston Scientific$88
- Amarin Pharma, Inc.$76
- plus $516 from 16 others
What the payments were for
- Food & beverage$1,03495%
- Education$545%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $105 |
| Baxter Healthcare | 1 | $105 |
| Boehringer Ingelheim | 7 | $101 |
| Shire North American Group Inc | 6 | $98 |
| Boston Scientific | 3 | $88 |
| Amarin Pharma, Inc. | 5 | $76 |
| CSL Behring | 4 | $71 |
| Pharming Healthcare, Inc. | 3 | $57 |
| Pfizer | 4 | $51 |
| Mannkind Corporation | 1 | $43 |
| Novo Nordisk | 3 | $42 |
| Bayer | 2 | $40 |
| Amgen | 2 | $39 |
| AbbVie(2 entities) | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Lilly USA, LLC | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Merck | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| GSK | 1 | $13 |
| Corcept Therapeutics | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOSEAL$105
How this compares
$1,088 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RuconestC1 Esterase Inhibitor, Recomb | 13 | $777,929 |
| EliquisApixaban | 1,143 | $330,926 |
| JardianceEmpagliflozin | 373 | $281,028 |
| FarxigaDapagliflozin Propanediol | 233 | $154,761 |
| OzempicSemaglutide | 89 | $107,100 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $106,115 |
| MounjaroTirzepatide | 97 | $99,994 |
| LinzessLinaclotide | 136 | $90,230 |
| MyrbetriqMirabegron | 336 | $82,194 |
| NuplazidPimavanserin Tartrate | 59 | $81,363 |
| TrulicityDulaglutide | 65 | $72,389 |
| XareltoRivaroxaban | 178 | $63,304 |
| JanuviaSitagliptin Phosphate | 85 | $52,669 |
| VraylarCariprazine Hcl | 38 | $42,214 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 75 | $39,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharming Healthcare, Inc.Ruconest | $57 | $777,92913 claims |
| PfizerEliquis, Abrysvo | $51 | $342,8761,181 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $101 | $311,917396 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $105 | $175,106289 claims |
| Lilly USA, LLCMounjaro, Trulicity | $20 | $172,383162 claims |
| AbbVieLinzess, Vraylar | $36 | $132,443174 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $130,226195 claims |
| Novo NordiskOzempic, Rybelsus | $42 | $123,720102 claims |
| MerckJanuvia, Janumet | $15 | $85,828131 claims |
| Johnson & JohnsonXarelto | $14 | $63,304178 claims |
| AmgenProlia | $39 | $35,02121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Oneonta
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.